Patents by Inventor Kimio Terao
Kimio Terao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240158520Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: ApplicationFiled: August 31, 2023Publication date: May 16, 2024Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki KaishaInventors: Xiaoping Zhang, Kimio Terao
-
Publication number: 20230183365Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: ApplicationFiled: March 1, 2023Publication date: June 15, 2023Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki KaishaInventors: Xiaoping Zhang, Kimio Terao
-
Patent number: 11667720Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: March 1, 2023Date of Patent: June 6, 2023Assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki KaishaInventors: Xiaoping Zhang, Kimio Terao
-
Patent number: 11622969Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: May 9, 2022Date of Patent: April 11, 2023Assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki KaishaInventors: Xiaoping Zhang, Kimio Terao
-
Publication number: 20220280532Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: ApplicationFiled: May 9, 2022Publication date: September 8, 2022Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki KaishaInventors: Xiaoping Zhang, Kimio Terao
-
Publication number: 20210228597Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: ApplicationFiled: December 8, 2020Publication date: July 29, 2021Applicants: Hoffmann-La Roche Inc., CHUGAI SEIYAKU KABUSHIKI KAISHA, Genentech, Inc.Inventors: XIAOPING ZHANG, KIMIO TERAO, ANGELIKA M. JAHREIS, Min Bao
-
Patent number: 10874677Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: January 22, 2019Date of Patent: December 29, 2020Assignees: Hoffmann-La Roche Inc., CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Xiaoping Zhang, Kimio Terao
-
Publication number: 20190247403Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: ApplicationFiled: January 22, 2019Publication date: August 15, 2019Applicants: HOFFMANN-LA ROCHE INC., CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: XIAOPING ZHANG, KIMIO TERAO, JOHANNES F. SCHMIDT
-
Patent number: 10231981Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: August 3, 2017Date of Patent: March 19, 2019Assignees: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.Inventors: Xiaoping Zhang, Kimio Terao, Olivier Alfred Harari
-
Publication number: 20170360807Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: ApplicationFiled: August 3, 2017Publication date: December 21, 2017Applicants: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.Inventors: Xiaoping Zhang, Kimio Terao, Olivier Alfred Harari
-
Patent number: 9750752Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: October 24, 2013Date of Patent: September 5, 2017Assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki KaishaInventors: Xiaoping Zhang, Kimio Terao, Olivier Alfred Harari
-
Patent number: 9539263Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: October 24, 2013Date of Patent: January 10, 2017Assignees: Genentech, Inc., Hoffmann-La Roche, Inc., Chugai Seiyaku Kabushiki KaishaInventors: Xiaoping Zhang, Kimio Terao, Angelika M. Jahreis
-
Publication number: 20140056885Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: ApplicationFiled: October 24, 2013Publication date: February 27, 2014Applicants: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.Inventors: Xiaoping Zhang, Kimio Terao, Olivier Alfred Harari
-
Publication number: 20140056884Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: ApplicationFiled: October 24, 2013Publication date: February 27, 2014Applicants: Genentech, Inc., Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.Inventors: Xiaoping Zhang, Kimio Terao, Angelika M. Jahreis
-
Publication number: 20140056883Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: ApplicationFiled: October 24, 2013Publication date: February 27, 2014Applicants: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.Inventors: Xiaoping Zhang, Kimio Terao, Olivier Alfred Harari
-
Patent number: 8580264Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: November 7, 2011Date of Patent: November 12, 2013Assignees: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Xiaoping Zhang, Min Bao, Angelika M. Jahreis, Kimio Terao